Pfizer Inc - Elrexfio™ Shows Median Overall Survival of More Than Two Years in People With Relapsed or Refractory Multiple Myeloma
輝瑞公司——Elrexfio™在復發或難治性多發性骨髓瘤患者中顯示出中位總生存期超過兩年
Pfizer Inc - Elrexfio™ Shows Median Overall Survival of More Than Two Years in People With Relapsed or Refractory Multiple Myeloma
輝瑞公司——Elrexfio™在復發或難治性多發性骨髓瘤患者中顯示出中位總生存期超過兩年
譯文內容由第三人軟體翻譯。